` EDIT (Editas Medicine Inc) vs S&P 500 Comparison - Alpha Spread

EDIT
vs
S&P 500

Over the past 12 months, EDIT has underperformed S&P 500, delivering a return of -54% compared to the S&P 500's 9% growth.

Stocks Performance
EDIT vs S&P 500

Loading
EDIT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
EDIT vs S&P 500

Loading
EDIT
S&P 500
Difference
www.alphaspread.com

Performance By Year
EDIT vs S&P 500

Loading
EDIT
S&P 500
Add Stock

Competitors Performance
Editas Medicine Inc vs Peers

S&P 500
EDIT
ABBV
AMGN
GILD
VRTX
Add Stock

Editas Medicine Inc
Glance View

Market Cap
196.7m USD
Industry
Biotechnology

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

EDIT Intrinsic Value
2.67 USD
Undervaluation 12%
Intrinsic Value
Price
Back to Top